Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 10/20 | 0.72 |
| ▸ | CTSK | P43235 | 9/20 | 0.72 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13211222 | 0.88 | CTSS (0.71) | CTSSCTSKCTSBCTSLHDAC8 | |
| SCHEMBL5188769 | 0.88 | CTSS (0.72) | CTSSCTSKCTSBCTSLHDAC8 | |
| SCHEMBL5188418 | 0.88 | CTSS (0.72) | CTSSCTSKCTSBCTSLHDAC8 | |
| SCHEMBL7273440 | 0.88 | CTSS (0.72) | CTSSCTSKCTSBCTSLHDAC8 | |
| SCHEMBL8268491 | 0.87 | CTSS (0.57) | CTSSCTSKCTSBCTSLHDAC8 | |
| SCHEMBL479234 | 0.86 | CTSS (0.72) | CTSSCTSKCTSBCTSL | |
| SCHEMBL6163823 | 0.86 | CTSS (0.73) | CTSSCTSKCTSBCTSLHDAC8 | |
| SCHEMBL479232 | 0.86 | CTSS (0.72) | CTSSCTSKCTSBCTSL | |
| SCHEMBL2109180 | 0.86 | CTSS (0.72) | CTSSCTSKCTSBCTSL | |
| SCHEMBL6163323 | 0.86 | CTSS (0.73) | CTSSCTSKCTSBCTSLHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059175-A1 | Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED | 2025-02-20 | — | — | US | disclosed |
| EP-1480946-A2 | A HYDROXAMIC ACID THROMBOSPONDIN PEPTIDE ANALOG THAT INHIBITS AGGRECANASE ACTIVITY | MP Biomedicals, L.L.C. (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030114529-A1 | HO-NH-(C=O)-CH2-CH(-CH2-CH(CH3)2)-(C=O)-V-,V=valine or another amino acid connected with an amino acid sequence of 10 or more amino acids; useful for treating diseases caused by cartilage degradation | MP BIOMEDICALS, LLC | 2003-06-19 | — | — | US | disclosed |
| WO-2003005956-A2 | A HYDROXAMIC ACID THROMBOSPONDIN PEPTIDE ANALOG THAT INHIBITS AGGRECANASE ACTIVITY | ENZYME SYSTEMS PRODUCTS, INC. /(ICN - BIOMEDICALS) (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059175-A1 | Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals | PIK3CA, PIK3CD, PIK3R5 | CTSS 2804/4885CTSK 2347/4885CTSB 2501/4885 |
| US-20030114529-A1 | HO-NH-(C=O)-CH2-CH(-CH2-CH(CH3)2)-(C=O)-V-,V=valine or another amino acid connected with an amino acid sequence of 10 or more amino acids; useful for treating diseases caused by cartilage degradation | HGFAC, ASPH, SYVN1 | CTSS 422/4885CTSK 491/4885CTSB 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.